Rabeprazole: Pharmacokinetics in patients with stable, compensated cirrhosis

Clinical Therapeutics

Volumn 21, Issue 4, 1999, Pages 691-701

  Hoyumpa, Anastacio M ^a   Trevino Alanis, Hector ^a   Grimes, Imogene ^b   Humphries, Thomas J ^c  

^a SOUTH TEXAS VETERANS HEALTH CARE SYSTEM   (United States)

^b CATO RESEARCH LTD   (United States)

^c EISAI CO LTD   (Japan)

Author keywords

Cirrhosis; Proton pump inhibitors; Rabeprazole

Indexed keywords

CALCIUM; CHLORIDE; CREATININE; HYDROGEN POTASSIUM ADENOSINE TRIPHOSPHATASE; LACTATE DEHYDROGENASE; PHOSPHORUS; PROTON PUMP; PROTON PUMP INHIBITOR; RABEPRAZOLE; SODIUM; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG TOLERABILITY; DUODENUM ULCER; ELECTROCARDIOGRAM; GASTROESOPHAGEAL REFLUX; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER DYSFUNCTION; LIVER SCINTISCANNING; MALE; SPLEEN SCINTISCANNING; STOMACH ULCER;

EID: 0033014908     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(00)88320-4     Document Type: Article

References (39)

1. + ATPase. Annu Rev Pharmacol Toxicol. 1995;35:277-305.
2. Chiba N, Matisko A, Sinclair P, Thomson AB. Helicobacter pylori: From bench to bedside. Can J Gastroenterol. 1997;11: 589-596.
3. Lambert R. Review article: Current practice and future perspectives in the management of gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 1997; 1:651-662.
4. Huang JQ, Hunt RH. pH, healing rate and symptom relief in acid-related diseases. Yale J Biol Med. 1996;69:159-174.
5. 2-receptor antagonists in acid-related diseases. Eur J Gastroenterol Hepatol. 1996;8 (Suppl 1):S3-S7.
6. Forné M, Viver JM, Esteve M, et al. Randomized clinical trial comparing two one-week triple-therapy regimens for the eradication of Helicobacter pylori infection and duodenal ulcer healing. Am J Gastroenterol. 1998;93:35-38.
7. Prakash A, Faulds D. Rabeprazole. Drugs. 1998;55:261-267.
8. Humphries TJ, Spera A, Breiter J, et al. Rabeprazole sodium once daily is superior to ranitidine 150 mg bid in the healing of active duodenal ulcer. Gastroenterology. 1997;112:A154. Abstract.
9. Humphries TJ, Spera A, Breiter J, et al. Rabeprazole sodium (E3810) once daily is superior to ranitidine 150 mg QID in the healing of erosive or ulcerative gastroesophageal reflux disease. Gastroenterology. 1996;110:A139. Abstract.
10. Zimmermann AE, Katona BG. Lansoprazole: A comprehensive review. Pharmacotherapy. 1997;17:308-326.
11. Fitton A, Wiseman L. Pantoprazole: A review of its pharmacological properties and therapeutic use in acid-related disorders. Drugs. 1996;51:460-482.
12. Poynard T, Lemaire M, Agostini H. Meta-analysis of randomized clinical trials comparing lansoprazole with ranitidine or famotidine in the treatment of acute duodenal ulcer. Eur J Gastroenterol Hepatol. 1995; 7:661-665.
13. Beker JA, Dekkers CPM, Thjodleifsson B, et al. Rabeprazole sodium 20 mg once daily is similar to omeprazole 20 mg once daily in the healing of active duodenal ulcer. Gastroenterology. 1997;112:A70. Abstract.
14. Thjodleifsson B, Dekkers CPM, Beker JA, et al. Rabeprazole sodium 20 mg once daily is similar to omeprazole 20 mg once daily in the treatment of erosive or ulcerative GERD. Gastroenterology. 1997;112: A312. Abstract.
15. Dekkers CPM, Beker JA, Thjodleifsson B, et al. Comparison of rabeprazole 20 mg vs. omeprazole 20 mg in the treatment of active gastric ulcer - A European multicentre study. Aliment Pharmacol Ther. 1998;12:789-795.
16. Benet LZ, Zech K. Pharmacokinetics: A relevant factor for the choice of a drug? Aliment Pharmacol Ther. 1994;8(Suppl 1):25-32.
17. Humphries TJ. Clinical implications of drug interactions with the cytochrome P-450 enzyme system associated with omeprazole. Dig Dis Sci. 1991;36:1665-1669.
18. Ishizaki T, Chiba K, Manabe K, et al. Comparison of the interaction potential of a new proton pump inhibitor, E3810, versus omeprazole with diazepam in extensive and poor metabolizers of S-mephenytoin 4′-hydroxylation. Clin Pharmacol Ther. 1995;58:155-164.
19. Humphries TJ, Nardi RV, Lazar JD, Spanyers SA. Drug-drug interaction evaluation of rabeprazole sodium: A clean/expected slate? Gut. 1996;39(Suppl 3):A47. Abstract.
20. Iber FL, Murphy PA, Connor ES. Age-related changes in the gastrointestinal system. Effects on drug therapy. Drugs Aging. 1994;5:34-48.
21. Freston MS, Freston JW. Peptic ulcers in the elderly: Unique features and management. Geriatrics. 1990;45:39-42.
22. The 1983 Metropolitan Life Insurance Height and Weight Tables. New York: Metropolitan Life Insurance Company; 1983.
23. Yasuda S, Ohnishi A, Ogawa T, et al. Pharmacokinetic properties of E3810, a new proton pump inhibitor, in healthy male volunteers. Int J Clin Pharmacol Ther. 1994;32:466-473.
24. Spera A, Merritt J, Keane W, et al. Rabeprazole 20 mg does not require dosage adjustment in elderly patients or those with renal or hepatic disease. Digestion. 1998; 59(Suppl 3):76. Abstract.
25. Humphries TJ, Keane WF, St. Peter JV, et al. Rabeprazole: Safety, tolerance, and pharmacokinetics in patients with renal dysfunction. Am J Gastroenterol. 1998;93: 1638. Abstract.
26. Rabeprazole [package insert]. Teaneck, NJ; Eisai Inc.; 1999.
27. Misiewicz JJ. Expert report: Clinical. E3810 or rabeprazole sodium. Data on file. London: Eisai Europe Limited; 1998.
28. VandenBranden M, Ring BJ, Binkley SN, Wrighton SA. Interaction of human liver cytochromes P450 in vitro with LY307640, a gastric proton pump inhibitor. Pharmacogenetics. 1996;6:81-91.
29. Walker S, Klotz U, Sarem-Aslani A, et al. Effect of omeprazole on nocturnal intragastric pH in cirrhotics with inadequate antisecretory response to ranitidine. Digestion. 1991;48:179-184.
30. Rinetti M, Regazzi MB, Villani P, et al. Pharmacokinetics of omeprazole in cirrhotic patients. Arzneim-Forsch Drug Res. 1991;41:420-422.
31. 14MC] omeprazole in patients with liver cirrhosis. Clin Pharmacokinet. 1993;24:71-78.
32. Del Río Fernández M del C, Plagaro Cordero ME, de Frutos Arribas JF, et al. Encefalopatía hepática relacíonada con omeprazole. Rev Esp Enferm Dig. 1997;89:574-575.
33. Jochem V, Kirkpatrick R, Greenson J, et al. Fulminant hepatic failure related to omeprazole. Am J Gastroenterol. 1992;87:523-525.
34. Delhotal-Landes B, Flouvat B, Duchier J, et al. Pharmacokinetics of lansoprazole in patients with renal or liver disease of varying severity. Eur J Clin Pharmacol. 1993;45:367-371.
35. Huber R, Hartmann M, Bliesath H, et al. Pharmacokinetics of pantoprazole in man. Int J Clin Pharmacol Ther. 1996;34(Suppl 1):S7-S16.
36. Spatzenegger M, Jaeger W. Clinical importance of hepatic cytochrome P450 in drug metabolism. Drug Metab Rev. 1995; 27:397-417.
37. Delhotal-Landes B, Petite JP, Flouvat B. Clinical pharmacokinetics of lansoprazole. Clin Pharmacokinet. 1996;28:458-470.
38. Steíníjans VW, Huber R, Hartmann M, et al. Lack of pantoprazole drug interactions in man. Int J Clin Pharmacol Ther. 1994; 32:385-399.
39. Cloud ML, Enas N, Humphries TJ, Bassion S. Rabeprazole in treatment of acid peptic diseases: Results of three placebo-controlled dose-response clinical trials in duodenal ulcer, gastric ulcer, and gastroesophageal reflux disease (GERD). Dig Dis Sci. 1998;43:993-1000.